Menu Close

MyMD Pharmaceuticals Enrolls First Individual in Stage 2 Professional Trial of MYMD-1 as a Therapy for Delaying Aging and Increasing Healthy And Balanced Lifespan

MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc (” MyMD” or “the Business”), a medical phase pharmaceutical firm dedicated to expanding healthy life-span, today revealed that the very first client has actually been registered in the Firm’s Phase 2 clinical trial of lead prospect MYMD-1, a dental immune regulatory authority medicine, as a therapy for delaying aging as well as broadening healthy life expectancy.

The main endpoint for the Phase 2 double-blind, placebo-controlled clinical test is to achieve a decrease in the circulating levels of (TNF-α), tumor death aspect receptor I (TNFRI) and also IL-6. TNF-α as well as IL-6 are the healthy proteins in the body that create swelling and also help activate the process of aging. The additional measures of the test will be the safety and security, tolerability, and pharmacokinetics in this population of patients.

” In a Phase 1 medical test of MYMD-1, we demonstrated the medication’s statistically considerable efficiency in lowering levels of TNF-α, a principal in causing pathological aging, in the blood. The FDA has approved TNF-α decrease as the key endpoint for our Stage 2 research study, which we believe placements us well for a successful Stage 2 result,” stated Chris Chapman, M.D., President, Director as well as Chief Medical Police Officer of MyMD. “The initiation of patient registration in this research advances our objective to reduce the aging process, protect against loss of muscle tissue in aging, restriction frailty, and extend healthy life expectancy.”

MyMD has actually mentioned that there are no FDA-approved medicines for dealing with aging conditions and also expanding healthy life-span humans, a market anticipated to be a minimum of $600 billion by 20251 according to a significant financial investment bank. TNF-α blockers are one of the most proposed medicines by profits, an international market of around $40 billion each year,2 as well as, according to Nature Aging journal,3 a slowdown in maturing that would certainly enhance life expectancy by one year is worth $38 trillion as well as by ten years deserves $367 trillion.

In addition to aging, MYMD-1’s distinctive action in controling the body immune system and also treating persistent inflammation is being created for the therapy of autoimmune condition, including rheumatoid joint inflammation (RA), multiple sclerosis (MS), diabetes, as well as inflammatory digestive tract illness.

” We intend to begin composing methods for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman kept in mind. “The rising frequency of rheumatoid arthritis and various other autoimmune and also inflammatory diseases are driving need for TNF preventions like MYMD-1, and also we believe our orally provided medicine with extremely low poisoning would be disruptive to the $60 billion market for RA if accepted by the FDA for this sign.”

Rheumatoid arthritis influences approximately 40 million individuals worldwide.4.

About MYMD-1.

Originally developed for autoimmune illness, MYMD-1’s main function is to slow down the aging procedure, stop sarcopenia and also frailty, and prolong healthy and balanced life-span. Due to the fact that it can go across the blood-brain obstacle and get to the main nerve system (CNS), MYMD-1 is additionally positioned to be a possible treatment for brain-related conditions. Its device of action as well as effectiveness in conditions consisting of numerous sclerosis (MS) as well as thyroiditis have actually been examined through cooperations with several academic organizations. MYMD-1 is likewise revealing promise in pre-clinical researches as a possible treatment for post- COVID-19 complications and as an anti-fibrotic as well as anti-proliferation therapeutic.

MYMD-1 has actually shown efficiency in pre-clinical researches in controling the immune system by performing as a careful inhibitor of growth necrosis factor-alpha (TNF-α), a chauffeur of chronic swelling. Unlike various other treatments, MYMD-1 has actually been displayed in these pre-clinical researches to precisely block TNF-α when it ends up being overactivated in autoimmune diseases and also cytokine storms, yet not obstruct it from doing its normal job of being a first -responder to any routine type of modest infection. MYMD-1’s ease of dental dosing is another differentiator contrasted to presently available TNF-α blockers, every one of which call for distribution by injection or infusion. No authorized TNF prevention has actually ever been dosed orally. On top of that, the drug is not immunosuppressive as well as has actually not been shown to cause the significant negative effects usual with typical treatments that treat swelling.

Concerning MyMD Pharmaceuticals, Inc

. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a scientific phase pharmaceutical business dedicated to extending healthy life-span, is focused on developing two unique healing systems that treat the root causes of disease rather than only addressing the signs. MYMD-1 is a medication system based upon a medical phase small molecule that manages the immune system to manage TNF-α, which drives chronic inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, increase durability, as well as deal with autoimmune diseases and COVID-19- associated clinical depression. The Business’s second medicine platform, Supera-CBD, is being developed to treat persistent discomfort, dependency and also epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and also is being developed to deal with and surpass the swiftly growing CBD market, which includes both FDA approved medicines as well as CBD items not presently controlled as medications. For more information, see www.mymd.com.